SAR445877 for Advanced Cancer
Trial Summary
What is the purpose of this trial?
This trial tests a new drug, SAR445877, for adults with advanced cancers that are hard to treat. The study will find the best amount to use and check if the drug is safe and works well, both alone and with other treatments.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are on ongoing corticosteroid therapy or have certain health conditions, you may not be eligible to participate. It's best to discuss your specific medications with the trial team.
Research Team
Clinical Sciences & Operations
Principal Investigator
Sanofi
Eligibility Criteria
Adults with advanced solid tumors that can't be surgically removed or have spread, and who lack suitable standard treatments. Specific groups include those with certain types of lung, stomach, liver cancers, and gastroesophageal junction adenocarcinoma. Participants must have measurable disease and give informed consent.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Finding the therapeutic dose(s) of SAR445877 in monotherapy and in combination with other anticancer therapies
Dose Expansion/Optimization
Assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- SAR445877 (Monoclonal Antibodies)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi
Lead Sponsor
Paul Hudson
Sanofi
Chief Executive Officer since 2019
Degree in Economics from Manchester Metropolitan University
Christopher Corsico
Sanofi
Chief Medical Officer
MD from Cornell University, MPH in Chronic Disease Epidemiology from Yale University